283 related articles for article (PubMed ID: 20622004)
1. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1.
Slattery ML; Herrick JS; Lundgreen A; Fitzpatrick FA; Curtin K; Wolff RK
Carcinogenesis; 2010 Sep; 31(9):1604-11. PubMed ID: 20622004
[TBL] [Abstract][Full Text] [Related]
2. Diet and colorectal cancer: analysis of a candidate pathway using SNPS, haplotypes, and multi-gene assessment.
Slattery ML; Lundgreen A; Herrick JS; Caan BJ; Potter JD; Wolff RK
Nutr Cancer; 2011 Nov; 63(8):1226-34. PubMed ID: 21999454
[TBL] [Abstract][Full Text] [Related]
3. Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway.
Slattery ML; Lundgreen A; Herrick JS; Caan BJ; Potter JD; Wolff RK
Carcinogenesis; 2011 Mar; 32(3):318-26. PubMed ID: 21088106
[TBL] [Abstract][Full Text] [Related]
4. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer.
Slattery ML; Lundgreen A; Herrick JS; Wolff RK
Mutat Res; 2011 Jan; 706(1-2):13-20. PubMed ID: 21035469
[TBL] [Abstract][Full Text] [Related]
5. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with colorectal cancer.
Lee SJ; Kang BW; Chae YS; Kim HJ; Park SY; Park JS; Choi GS; Jeon HS; Lee WK; Kim JG
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S634-9. PubMed ID: 24770722
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
[TBL] [Abstract][Full Text] [Related]
7. Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy.
Hildebrandt MA; Yang H; Hung MC; Izzo JG; Huang M; Lin J; Ajani JA; Wu X
J Clin Oncol; 2009 Feb; 27(6):857-71. PubMed ID: 19164214
[TBL] [Abstract][Full Text] [Related]
8. Genetic variation in bone morphogenetic protein and colon and rectal cancer.
Slattery ML; Lundgreen A; Herrick JS; Kadlubar S; Caan BJ; Potter JD; Wolff RK
Int J Cancer; 2012 Feb; 130(3):653-64. PubMed ID: 21387313
[TBL] [Abstract][Full Text] [Related]
9. Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival.
Slattery ML; Curtin K; Poole EM; Duggan DJ; Samowitz WS; Peters U; Caan BJ; Potter JD; Ulrich CM
Int J Cancer; 2011 Jun; 128(11):2726-34. PubMed ID: 20949557
[TBL] [Abstract][Full Text] [Related]
10. Somatic alterations, metabolizing genes and smoking in rectal cancer.
Curtin K; Samowitz WS; Wolff RK; Herrick J; Caan BJ; Slattery ML
Int J Cancer; 2009 Jul; 125(1):158-64. PubMed ID: 19358278
[TBL] [Abstract][Full Text] [Related]
11. The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes.
Li X; Zhang R; Liu Z; Li S; Xu H
Oncotarget; 2017 Mar; 8(12):20252-20265. PubMed ID: 28423632
[TBL] [Abstract][Full Text] [Related]
12. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
13. Mosaic Disorders of the PI3K/PTEN/AKT/TSC/mTORC1 Signaling Pathway.
Nathan N; Keppler-Noreuil KM; Biesecker LG; Moss J; Darling TN
Dermatol Clin; 2017 Jan; 35(1):51-60. PubMed ID: 27890237
[TBL] [Abstract][Full Text] [Related]
14. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
Wang LE; Ma H; Hale KS; Yin M; Meyer LA; Liu H; Li J; Lu KH; Hennessy BT; Li X; Spitz MR; Wei Q; Mills GB
J Cancer Res Clin Oncol; 2012 Mar; 138(3):377-85. PubMed ID: 22146979
[TBL] [Abstract][Full Text] [Related]
15. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer.
Li Q; Yang J; Yu Q; Wu H; Liu B; Xiong H; Hu G; Zhao J; Yuan X; Liao Z
Clin Cancer Res; 2013 Nov; 19(22):6252-60. PubMed ID: 24077347
[TBL] [Abstract][Full Text] [Related]
16. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
17. MAP kinase genes and colon and rectal cancer.
Slattery ML; Lundgreen A; Wolff RK
Carcinogenesis; 2012 Dec; 33(12):2398-408. PubMed ID: 23027623
[TBL] [Abstract][Full Text] [Related]
18. Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes.
Miyazaki M; McCarthy JJ; Esser KA
FEBS J; 2010 May; 277(9):2180-91. PubMed ID: 20412061
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability and survival in rectal cancer.
Samowitz WS; Curtin K; Wolff RK; Tripp SR; Caan BJ; Slattery ML
Cancer Causes Control; 2009 Nov; 20(9):1763-8. PubMed ID: 19669908
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathway.
Presneau N; Shalaby A; Idowu B; Gikas P; Cannon SR; Gout I; Diss T; Tirabosco R; Flanagan AM
Br J Cancer; 2009 May; 100(9):1406-14. PubMed ID: 19401700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
